AU2001277863A1 - Radioligand and binding assay - Google Patents

Radioligand and binding assay

Info

Publication number
AU2001277863A1
AU2001277863A1 AU2001277863A AU7786301A AU2001277863A1 AU 2001277863 A1 AU2001277863 A1 AU 2001277863A1 AU 2001277863 A AU2001277863 A AU 2001277863A AU 7786301 A AU7786301 A AU 7786301A AU 2001277863 A1 AU2001277863 A1 AU 2001277863A1
Authority
AU
Australia
Prior art keywords
radioligand
binding assay
hydoxyspiro
naphthalenyl
methanesulfonamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001277863A
Other languages
English (en)
Inventor
John W. Butcher
David A. Claremon
Thomas M. Connolly
Dennis C. Dean
Jerzy Karczewski
Kenneth S Koblan
Matthew J. Kostura
Nigel J. Liverton
David G. Melillo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of AU2001277863A1 publication Critical patent/AU2001277863A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0476—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from monodendate ligands, e.g. sestamibi
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2001277863A 2000-07-14 2001-07-10 Radioligand and binding assay Abandoned AU2001277863A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21839700P 2000-07-14 2000-07-14
US60218397 2000-07-14
PCT/US2001/021731 WO2002005860A1 (en) 2000-07-14 2001-07-10 Radioligand and binding assay

Publications (1)

Publication Number Publication Date
AU2001277863A1 true AU2001277863A1 (en) 2002-01-30

Family

ID=22814940

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001277863A Abandoned AU2001277863A1 (en) 2000-07-14 2001-07-10 Radioligand and binding assay

Country Status (9)

Country Link
US (1) US6838291B2 (es)
EP (1) EP1311300B1 (es)
JP (1) JP2004512268A (es)
AT (1) ATE387222T1 (es)
AU (1) AU2001277863A1 (es)
CA (1) CA2415295C (es)
DE (1) DE60133010T2 (es)
ES (1) ES2300345T3 (es)
WO (1) WO2002005860A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0121440D0 (en) * 2001-09-04 2001-10-24 Pfizer Ltd Assay
MXPA04002058A (es) * 2001-09-04 2004-06-07 Pfizer Prueba.
US6743797B2 (en) * 2002-02-22 2004-06-01 Chantest, Inc. Methods for treating cardiac arrhythmia
SE0302775D0 (sv) * 2003-10-20 2003-10-20 Astrazeneca Ab Chemical compound and assay
US7927820B2 (en) 2004-07-20 2011-04-19 Janssen Pharmaceutica Nv Assay systems and methods for detecting molecules that interact with membrane channels
US7326772B2 (en) * 2005-05-12 2008-02-05 Penta Biotech, Inc. Peptide for assaying hERG channel binding
JP2011517317A (ja) * 2008-02-28 2011-06-02 ライフ テクノロジーズ コーポレーション 蛍光偏光ｈＥＲＧアッセイ法
CA2714617A1 (en) 2008-03-06 2009-09-11 Banyu Pharmaceutical Co., Ltd. Alkylaminopyridine derivative
US10412788B2 (en) 2008-06-13 2019-09-10 Lg Chem, Ltd. Heating element and manufacturing method thereof
WO2009155283A2 (en) * 2008-06-17 2009-12-23 Duke University Radiolabled cyclopamine assay for the smoothened receptor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206240A (en) * 1989-12-08 1993-04-27 Merck & Co., Inc. Nitrogen-containing spirocycles
US5382587A (en) * 1993-06-30 1995-01-17 Merck & Co., Inc. Spirocycles
WO1995023146A1 (en) * 1994-02-25 1995-08-31 Merck & Co., Inc. Morphological forms of (+)-n-[1'-(6-cyano-1,2,3,4-tetrahydro-2-naphthalenyl)-3,4-dihydro-4-hydroxyspiro[2h-1-benzopyran-2,4'-piperidin]yl]methanesulfonamide hydrochloride
WO1997022367A1 (en) * 1995-12-20 1997-06-26 Merck & Co., Inc. Radiolabeled growth hormone secretagogue

Also Published As

Publication number Publication date
ATE387222T1 (de) 2008-03-15
JP2004512268A (ja) 2004-04-22
CA2415295A1 (en) 2002-01-24
EP1311300B1 (en) 2008-02-27
US20020034730A1 (en) 2002-03-21
WO2002005860A1 (en) 2002-01-24
ES2300345T3 (es) 2008-06-16
CA2415295C (en) 2010-02-16
EP1311300A4 (en) 2004-11-03
EP1311300A1 (en) 2003-05-21
DE60133010T2 (de) 2009-03-19
DE60133010D1 (de) 2008-04-10
US6838291B2 (en) 2005-01-04

Similar Documents

Publication Publication Date Title
AU2001277863A1 (en) Radioligand and binding assay
AU1743201A (en) Receptor binding conjugates
AU5993498A (en) Seal for reagent flask usable by a blood analyser
AU9298198A (en) Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity
AU3669199A (en) Methods of identifying and using hla binding compounds as hla-agonists and antagonists
WO1998009647A3 (en) Cyanidin compositions and therapeutic and diagnostic uses therefor
WO2002012224A3 (en) Bicyclic compounds as h3 receptor ligands
HUP0400294A3 (en) Method for preparation of (s)-(+)- and (r)-(-)-10,11-dihydro-10-hydroxy-5h-dibenz/b,f/azepine-5-carboxamide
AU8974298A (en) 1,4,7,10-tetraazabicyclo{8.2.2}tetradecan-2-one, a process for the preparation thereof and the use thereof for the preparation of tetraazamacrocycles
SV1999000060A (es) Procedimiento para la preparacion de (s,s)-bencil-2,8-diazabiciclo 4.3.0 nonano ref. 32965-sv
WO2003017930A3 (en) Reagents that facilitate the purification of compounds synthesized on a solid support
AU2001271841A1 (en) Methods for identifying combinations of drugs
AU7212198A (en) Preparation of blood samples for detecting homocysteine and/or folate
MX9800357A (es) Nuevo procedimiento para la preparacion de norbenzomorfano, una etapa intermedia en la preparacion de derivados de benzomorfano farmaceuticamente valiosos, especialmente de (-)-(ir, 5s, 2"r)-3'-hidroxi-2-(2-metoxipropil)-5,9,9-trimetil-6,7-benzom orf
WO2001082871A3 (en) Method of using zinc isotope for therapy and diagnosis of colon cancer
AU5250899A (en) Method and system for the determination of a ternary refrigerant mixture composition
AU2426095A (en) Aziridine compounds, methods of preparation and reactions thereof
WO1997026920A3 (de) Konjugat zur unterscheidung von krankhaftem und gesundem gewebe
WO1999005521A3 (de) Konjugat zur unterscheidung von krankhaftem und gesundem gewebe
EP0881277B8 (en) Use of metal sulfonates as friction modifiers
AU5115598A (en) Novel pentaerythritol derivatives, preparation and use thereof and intermediates for the synthesis thereof
DE59712604D1 (de) Mittel zur identifizierung und therapie metastasierender tumore
WO2002038803A3 (de) Neue marker für die diagnose und therapie von tumoren
WO2001071346A3 (en) Binding compounds for cc chemokine receptor 5 and methods for identifying them
WO2003038441A3 (en) Screening methods based on cited family proteins